{"Q": 1, "answer": "no", "rationale": "The segment does not contain an intensifier or comparative directly modifying a risk-adjective from the specified list.", "method": "llm_batch", "batch_id": "batch_1_17416", "batch_size": 200, "batch_pos": 162, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 2, "answer": "no", "rationale": "No high-potency verb, potent metaphor, superlative + harm noun, intensifier + harm noun, or critical alert phrase found.", "method": "llm_batch", "batch_id": "batch_2_20148", "batch_size": 200, "batch_pos": 123, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 3, "answer": "no", "rationale": "No moderate verb from the list paired with explicit scale/impact.", "method": "llm_batch", "batch_id": "batch_3_14272", "batch_size": 200, "batch_pos": 55, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 4, "answer": "no", "rationale": "The segment does not contain a question.", "method": "llm_batch", "batch_id": "batch_4_8792", "batch_size": 200, "batch_pos": 49, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 5, "answer": "no", "rationale": "The segment mentions advantages of technology but contains no explicit calming cues.", "method": "llm_batch", "batch_id": "batch_5_16576", "batch_size": 200, "batch_pos": 43, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 6, "answer": "no", "rationale": "Segment does not contain a minimiser word combined with a scale contrast.", "method": "llm_batch", "batch_id": "batch_6_19532", "batch_size": 200, "batch_pos": 196, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 7, "answer": "no", "rationale": "Segment does not contain a bare negation.", "method": "llm_batch", "batch_id": "batch_7_16788", "batch_size": 200, "batch_pos": 180, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
{"Q": 8, "answer": "yes", "rationale": "Describes a capability/future possibility ('technology offers advantages') without active reassurance.", "method": "llm_batch", "batch_id": "batch_8_18904", "batch_size": 200, "batch_pos": 16, "statement_text": "mRNA vaccine technology offers advantages in efficacy, speed of development and production, scalability, and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic, Moderna CEO Stephane Bancel said in a statement.", "article_id": 1745}
